Genotypes of the human papillomavirus: relevance to Indian field trials of the vaccine.
Highly effective HPV vaccines are likely to become available for use in India shortly. The availability and validation of the vaccines to prevent oncogenic HPV infection associated lesions from progressing to cancer has clearly offered a cost effective long-term strategy to reduce the cervical cancer burden, particularly for developing countries where effective screening programmes are not available. The enthusiasm for these new vaccines duly justified, are we in reality targeting the actual delinquent by prompting these vaccines in India? The answer would be no as we may not be essentially implementing a rational fool-proof vaccine program which will aid in preventing HPV-related diseases, for the simple reason that there is a lack of understanding about the underlying HPV types responsible for cervical cancer in India. Field trials involving large populations form a major part of continued analysis in understanding any disease and India is still short of such a trial as far as cervical cancer is concerned. Conducting such studies, might also act as prevention programs that will save lives and improve public health in a substantive manner.
Hariharan
Indhu
I
Laboratory of Translational Cancer Research, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.
Pillai
M Radhakrishna
MR
D002986:Clinical Trials as Topic; D005260:Female; D005838:Genotype; D006801:Humans; D007194:India / Q000453:epidemiology; D008403:Mass Screening; D027383:Papillomaviridae / Q000145:classification / Q000235:genetics* / Q000472:pathogenicity; D053918:Papillomavirus Vaccines / Q000191:economics / Q000494:pharmacology*; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines